CKD on Med-Surg: Fluid Balance, Phosphate Binders, Erythropoietin, Dialysis Patients

CKD on Med-Surg: Fluid Balance, Phosphate Binders, Erythropoietin, Dialysis Patients

A high-density, practical guide for nurses and clinicians managing chronic kidney disease (CKD) in medical-surgical settings.

What Is This?

This guide covers fluid balance management, phosphate binders, erythropoietin (EPO) therapy, and dialysis care in patients with CKD. It provides immediately actionable knowledge for nurses and clinicians to optimize patient outcomes, prevent complications, and streamline care.

Why use it today? CKD affects 1 in 7 adults in the U.S., and med-surg units frequently manage these patients—whether for acute exacerbations, dialysis access issues, or electrolyte imbalances. Missteps in fluid balance, phosphate control, or anemia management can lead to hospitalizations, cardiovascular events, or death. This guide ensures safe, evidence-based care.

Why It Matters

• Fluid overload-Pulmonary edema, hypertension, heart failure.
• Hyperphosphatemia-Secondary hyperparathyroidism, bone disease, vascular calcification.
• Anemia-Fatigue, reduced quality of life, increased cardiac workload.
• Dialysis complications-Infections, access failure, hypotension, electrolyte shifts.

Real-world impact: - Reduces readmissions by preventing fluid overload and electrolyte crises. - Improves survival by managing anemia and mineral bone disease. - Enhances patient compliance through clear education on phosphate binders and fluid restrictions.

Core Concepts

1. Fluid Balance in CKD

• Kidneys lose ability to regulate fluid-Oliguria (low urine output) or anuria (no urine output) in late-stage CKD.
• Fluid overload (edema, crackles, hypertension) is more dangerous than dehydration in CKD.
• Daily weights are the most reliable way to monitor fluid status (1 kg = 1 L of fluid).
• Fluid restriction is often 1–1.5 L/day (varies by urine output + insensible losses).

2. Phosphate Binders

• Phosphate retention-Hyperphosphatemia-Secondary hyperparathyroidism (SHPT)-Renal osteodystrophy & vascular calcification.
• Binders work in the gut (not systemically) to prevent phosphate absorption from food.
• Timing is critical: Must be taken with meals (or within 30 min after) to bind dietary phosphate.
• Calcium-based vs. non-calcium-based:
• Calcium-based (e.g., calcium acetate, calcium carbonate)-Risk of hypercalcemia & vascular calcification.
• Non-calcium-based (e.g., sevelamer, lanthanum)-Preferred in hypercalcemic patients.

3. Erythropoietin (EPO) Therapy

• CKD causes anemia due to ? EPO production, iron deficiency, and chronic inflammation.
• EPO stimulates RBC production but requires adequate iron stores (check ferritin & TSAT).
• Target Hb: 10–11 g/dL (higher levels-thrombosis, hypertension, stroke risk).
• Darbepoetin alfa (Aranesp) is a longer-acting EPO analog (weekly/biweekly dosing).

4. Dialysis Patients on Med-Surg

• Types of dialysis access:
• AV fistula (gold standard)-Lowest infection risk, longest lifespan.
• AV graft-Higher infection/clotting risk, used if fistula fails.
• Central venous catheter (CVC)-Highest infection risk, temporary use only.
• Dialysis disequilibrium syndrome-Rapid solute removal-cerebral edema, seizures (prevent with slow, frequent dialysis).
• Hypotension during dialysis-Hold antihypertensives pre-dialysis, adjust ultrafiltration rate.

How It Works

Fluid Balance Management

1. Assess fluid status:
2. Daily weights (same scale, same time).
3. I&O tracking (urine output + insensible losses ~500–800 mL/day).
4. Physical exam: JVD, edema, crackles, BP trends.
5. Fluid restriction calculation:
6. Urine output + 500–800 mL (adjust for fever, diarrhea, vomiting).
7. Example: If urine output = 300 mL/day-Fluid restriction = 800–1,100 mL/day.
8. Diuretics (if residual kidney function):
9. Loop diuretics (furosemide)-Most effective in CKD.
10. Thiazides (HCTZ)-Ineffective if GFR <30 mL/min.

Phosphate Binders Mechanism

• Phosphate in food-Binds to binder in gut-Excreted in stool (not absorbed).
• Calcium-based binders also increase calcium absorption-Risk of hypercalcemia.
• Sevelamer (Renvela)-Non-absorbable polymer, lowers LDL cholesterol.

EPO Therapy Workflow

1. Check iron stores (ferritin >100 ng/mL, TSAT >20%).
2. Administer EPO (IV or SQ, usually 3x/week for epoetin alfa, weekly for darbepoetin).
3. Monitor Hb (goal 10–11 g/dL).
4. Adjust dose if Hb rises >1 g/dL in 2 weeks (risk of thrombosis).

Dialysis Care on Med-Surg

• Pre-dialysis assessment:
• Vital signs (BP, HR, temp).
• Access site (thrill/bruit for fistula/graft, signs of infection for CVC).
• Labs (K+, Ca2+, PO4-, Hb).
• Post-dialysis monitoring:
• Hypotension (common, treat with IV fluids, Trendelenburg position).
• Cramping (due to rapid fluid/electrolyte shifts-IV saline, adjust dialysate).
• Bleeding risk (heparin used during dialysis-hold pressure on access site).

Hands-On / Getting Started

Prerequisites

• Knowledge: Basic understanding of CKD pathophysiology, lab interpretation (BMP, CBC, iron studies).
• Skills: IV insertion, medication administration, fluid assessment.
• Tools: Stethoscope, BP cuff, scale, glucometer (for diabetic CKD patients).

Step-by-Step: Managing Fluid Overload

1. Assess patient:
2. Weight gain (>2 kg in 2 days = fluid overload).
3. Edema (pitting in legs, sacrum, lungs).
4. BP (hypertension common in fluid overload).
5. Intervene:
6. Fluid restriction (e.g., 1,000 mL/day).
7. Loop diuretic (e.g., furosemide 40–80 mg IV).
8. Monitor I&O (strict hourly if severe overload).
9. Evaluate:
10. Daily weights (goal: no further gain).
11. Lung sounds (clear = improvement).
12. BP trends (should decrease with diuresis).

Step-by-Step: Administering Phosphate Binders

1. Check PO4- level (goal: 3.5–5.5 mg/dL).
2. Select binder:
3. Hypercalcemic?-Sevelamer 800–1,600 mg PO with meals.
4. Hypocalcemic?-Calcium acetate 667 mg PO with meals.
5. Educate patient:
6. "Take with first bite of food" (or within 30 min).
7. "Do not take with other meds" (binders can interfere with absorption).
8. Monitor:
9. PO4- levels (recheck in 1–2 weeks).
10. Calcium levels (if using calcium-based binders).

Step-by-Step: EPO Therapy

1. Check iron studies (ferritin, TSAT).
2. If ferritin <100 ng/mL or TSAT <20%-Give IV iron (e.g., ferric gluconate 125 mg IV x3 doses).
3. Start EPO:
4. Epoetin alfa 50–100 units/kg SQ 3x/week.
5. Darbepoetin alfa 0.45 mcg/kg SQ weekly.
6. Monitor Hb:
7. Weekly until stable, then monthly.
8. If Hb >11 g/dL-Reduce dose by 25%.
9. Adjust for resistance:
10. Check for infection/inflammation (CRP, WBC).
11. Ensure adequate iron stores.

Step-by-Step: Dialysis Access Care

1. Assess access site:
2. Fistula/graft: Palpate thrill, auscultate bruit (absent = clot).
3. CVC: Check for redness, drainage, fever (signs of infection).
4. Prevent complications:
5. No BP/IV sticks in fistula arm.
6. Heparin lock for CVC (prevent clotting).
7. Post-dialysis care:
8. Hold pressure on access site (5–10 min for fistula, 10–15 min for graft).
9. Monitor for bleeding (apply pressure dressing if oozing).

Common Pitfalls & Mistakes

Best Practices

Fluid Balance

Weigh patients daily (same scale, same time). ? Calculate fluid restriction based on urine output + insensible losses. ? Use loop diuretics (furosemide) if residual kidney function exists. ? Avoid IV fluids unless hypovolemic (risk of overload).

Phosphate Binders

Give with meals (not before/after). ? Monitor calcium if using calcium-based binders. ? Switch to non-calcium binders if hypercalcemic. ? Don’t crush sevelamer (can cause esophageal irritation).

EPO Therapy

Check iron stores first (ferritin >100, TSAT >20%). ? Target Hb 10–11 g/dL (higher = thrombosis risk). ? Reduce dose if Hb rises >1 g/dL in 2 weeks. ? Don’t give EPO if active infection (? thrombosis risk).

Dialysis Care

Assess access site every shift (thrill/bruit for fistula/graft). ? Hold antihypertensives pre-dialysis (prevent hypotension). ? Monitor for disequilibrium syndrome (headache, nausea, seizures). ? Never use a dialysis CVC for IV fluids/meds (infection risk).

Tools & Frameworks

Real-World Use Cases

1. Fluid Overload in CKD Stage 4

Scenario: A 65-year-old male with CKD stage 4 (GFR 20 mL/min), HFpEF, and 3+ pitting edema is admitted for SOB. Action: - Daily weights (gained 4 kg in 3 days). - Strict I&O (urine output = 200 mL/day). - Furosemide 80 mg IV BID + fluid restriction (1,000 mL/day). - Monitor lung sounds (crackles improve with diuresis). Outcome: Weight loss of 3 kg in 48 hours, improved breathing.

2. Hyperphosphatemia in Dialysis Patient

Scenario: A 50-year-old female on hemodialysis has PO4- = 7.2 mg/dL (goal <5.5) and calcium = 9.8 mg/dL. Action: - Switch from calcium acetate to sevelamer 1,600 mg TID with meals. - Educate on phosphate-rich foods (dairy, nuts, soda). - Recheck PO4- in 2 weeks (drops to 4.8 mg/dL). Outcome: Reduced risk of vascular calcification, improved PTH control.

3. Anemia Management in CKD Stage 5

Scenario: A 70-year-old male with CKD stage 5 (GFR 10 mL/min) has Hb = 8.2 g/dL, ferritin = 80 ng/mL, TSAT = 15%. Action: - Give IV iron (ferric gluconate 125 mg x3 doses). - Start darbepoetin alfa 0.45 mcg/kg SQ weekly. - Monitor Hb weekly (rises to 10.5 g/dL in 4 weeks). Outcome: Improved energy, reduced transfusion need.

Check Your Understanding (MCQs)

Question 1

A patient with CKD stage 4 presents with 3+ pitting edema, crackles, and a 3 kg weight gain in 2 days. What is the most appropriate initial intervention?

A) Administer 0.9% NS 500 mL IV bolus B) Start furosemide 40 mg IV BID + fluid restriction (1,000 mL/day) C) Increase oral phosphate binders D) Hold all antihypertensives

Correct Answer: B Explanation: The patient has fluid overload (edema, weight gain, crackles). Loop diuretics + fluid restriction are first-line. IV fluids (A) would worsen overload. Phosphate binders (C) are unrelated. Holding antihypertensives (D) is only relevant pre-dialysis (not applicable here).

Why the Distractors Are Tempting: - A) "Give fluids" is a common reflex for hypotension, but this patient is overloaded. - C) Phosphate binders are important in CKD but not for acute fluid overload. - D) Holding antihypertensives is